Breaking News Instant updates and real-time market news.

CELG

Celgene

$100.10

-1.54 (-1.52%)

08:06
10/13/16
10/13
08:06
10/13/16
08:06

Celgene to present new data on investigational compounds at UEGW, ACG Congress

Celgene announced that findings from clinical trials of investigational compounds GED-0301, ozanimod and RPC4046 will be presented at the United European Gastroenterology Week, October 15-19, in Vienna, Austria. Ozanimod and RPC4046 data will also be included at the American College of Gastroenterology Annual Scientific Meeting, October 14-19, in Las Vegas. Among the data that will be presented is an ongoing, exploratory phase 1b study of GED-0301, an oral compound being investigated for active Crohn's disease. The ongoing study is evaluating the effects of three different regimens of oral GED-0301 on both endoscopic and clinical outcomes in patients with active Crohn's disease in a 12-week treatment phase, followed by an observation phase of up to 52 weeks. The study was designed to further enhance the understanding of GED-0301 activity in a difficult-to-treat, moderate-to-severe patient population. The data were accepted as a late breaking oral presentation at UEG Week. An analysis of the open-label extension of the TOUCHSTONE trial will evaluate the efficacy and safety of daily 1 mg oral ozanimod, an investigational selective S1p 1 and 5 receptor modulator, through week 44 of the open label extension in patients with moderate to severe ulcerative colitis. The 32 week double-blind placebo-controlled phase of TOUCHSTONE evaluated the efficacy and safety of 0.5 mg and 1 mg doses of ozanimod compared with placebo in patients with moderate to severe active ulcerative colitis. Results from this induction and maintenance phase of the trial have been previously reported. The open-label extension phase included TOUCHSTONE participants from all three treatment arms who either did not respond to treatment after the induction phase, relapsed during the maintenance phase or completed the maintenance phase. These results will be featured in an oral presentation at both ACG and UEG Week. Results from the phase 2 HEROES dose-ranging study will evaluate the efficacy and safety of RPC4046 in patients with active eosinophilic esophagitis, a rare but potentially serious allergic/immune disorder for which there are currently no approved treatments. RPC4046 is an investigational humanized monoclonal antibody that binds with high selectivity to both subunits of the IL-13 receptor. The data will be featured in an oral presentation at both ACG and UEG Week.

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$100.10

-1.54 (-1.52%)

09/12/16
PIPR
09/12/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer says Celgene GED-0301 data 'vague'
Piper Jaffray analyst Joshua Schimmer says he remains skeptical on the profile of Celgene's GED-0301 for Crohn's disease. This morning's "vague press release doesn't help despite the company's expressed confidence," Schimmer tells investors in a research note. He notes that while GED-0301 is not a relevant driver of his investment thesis, the drug is important to sentiment overall. The analyst reiterates an Overweight rating on Celgene.
09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.

TODAY'S FREE FLY STORIES

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:38
02/27/17
02/27
19:38
02/27/17
19:38
Hot Stocks
Priceline: 'Solid start' to Q1, shift of Easter into Q2 to pressure some metrics »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

19:33
02/27/17
02/27
19:33
02/27/17
19:33
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

, BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

19:28
02/27/17
02/27
19:28
02/27/17
19:28
Hot Stocks
Court rules in favor of Arctic Cat in Bombardier patent litigation »

Arctic Cat (ACAT)…

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:17
02/27/17
02/27
19:17
02/27/17
19:17
Hot Stocks
Priceline CFO: 'Hopeful' on promised Trump tax reform »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:16
02/27/17
02/27
19:16
02/27/17
19:16
Hot Stocks
Priceline says board approved new $2B buyback authorization »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

19:09
02/27/17
02/27
19:09
02/27/17
19:09
Hot Stocks
vTv Therapeutics sees reporting topline data from STEADFAST Part A in early 2018 »

Says STEADFAST Part B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:55
02/27/17
02/27
18:55
02/27/17
18:55
Earnings
AAC Holdings sees FY17 adjusted EPS 50c-58c, consensus 72c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CSX

CSX

$48.71

0.23 (0.47%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
CSX sees at least $160M charge from 'management streamlining' plan »

CSX disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$76.45

0.15 (0.20%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
Iowa American Water rate adjustment approved by IUB »

Following a 10-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:53
02/27/17
02/27
18:53
02/27/17
18:53
Hot Stocks
AAC Holdings sees over $8M in savings in 2017 from workforce reduction »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MORN

Morningstar

$81.62

-0.1 (-0.12%)

18:52
02/27/17
02/27
18:52
02/27/17
18:52
Hot Stocks
Morningstar CFO Stephane Biehler to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$248.60

3.55 (1.45%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Hot Stocks
Northrop Grumman appoints Pamiljans as aerospace systems president »

The board of Northrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Earnings
AAC Holdings reports Q4 adjusted EPS 15c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MS

Morgan Stanley

$45.84

0.31 (0.68%)

18:48
02/27/17
02/27
18:48
02/27/17
18:48
Hot Stocks
Morgan Stanley discloses erroneous client tax reporting, says in talks with IRS »

Morgan Stanley disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

MS

Morgan Stanley

$45.84

0.31 (0.68%)

, BK

BNY Mellon

$47.11

0.02 (0.04%)

18:47
02/27/17
02/27
18:47
02/27/17
18:47
Hot Stocks
Morgan Stanley says reached settlement in New York Mellon dispute »

Morgan Stanley (MS)…

MS

Morgan Stanley

$45.84

0.31 (0.68%)

BK

BNY Mellon

$47.11

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

OLN

Olin Corp.

$30.90

0.1 (0.32%)

18:41
02/27/17
02/27
18:41
02/27/17
18:41
Hot Stocks
Olin Corp. chairman Joseph Rupp to retire »

Olin Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 14

    Mar

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:35
02/27/17
02/27
18:35
02/27/17
18:35
Hot Stocks
Wheeler REIT revises dividend payment schedule »

Effective April 1, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:34
02/27/17
02/27
18:34
02/27/17
18:34
Hot Stocks
Ashford Hospitality: FelCor statements on proposal 'misguided and misleading' »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Ashford Hospitality Trust acknowledges Land and Buildings endorsement »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Wheeler REIT announces 1-for-8 reverse stock split »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

18:18
02/27/17
02/27
18:18
02/27/17
18:18
Earnings
vTv Therapeutics reports Q4 EPS (42c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:10
02/27/17
02/27
18:10
02/27/17
18:10
Hot Stocks
Delek Logistics targets 10% annual increase in distribution through 2019 »

CEO Yemin concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:06
02/27/17
02/27
18:06
02/27/17
18:06
Earnings
Delek Logistics reports Q4 EPS 47c, consensus 48c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DK

Delek US

$22.98

-0.21 (-0.91%)

18:06
02/27/17
02/27
18:06
02/27/17
18:06
Earnings
Delek US reports Q4 adjusted EPS (44c), consensus (55c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

KRA

Kraton Performance

$27.49

0.68 (2.54%)

18:01
02/27/17
02/27
18:01
02/27/17
18:01
Hot Stocks
Kraton Performance announces global Tall Oil Fatty Acids price increase »

Kraton announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.